二甲基丙二酸在小鼠急性呼吸窘迫综合征模型中保护肺组织
该研究为小鼠ARDS模型:C57BL/6小鼠经气管内给予67.7 μg脂多糖诱导ARDS,损伤后30分钟经尾静脉注射二甲基丙二酸(DMM)50 mg/kg,随后每日1次共3天,第4天处死行支气管肺泡灌洗(BAL)。与假注射组(n=8)相比,DMM组(n=8)BAL总细胞数、巨噬细胞和淋巴细胞均减少,BAL蛋白漏出减少,内皮糖萼(EGX)染色强度增加,体重下降程度更轻,单核细胞趋化蛋白-1和ICAM-1上调被抑制。作者认为DMM可减轻ARDS肺部炎症和毛细血管渗漏,可能通过保护EGX及抑制MCP-1和ICAM-1介导,可能成为ARDS的新型治疗。
要点
- 小鼠ARDS模型中,损伤后30分钟尾静脉注射DMM 50 mg/kg并每日1次共3天,BAL总细胞数DMM组6.93×10^6 vs 假注射组2.46×10^6(p=0.04)。
- DMM组BAL巨噬细胞168.6 vs 85.1(p=0.04)、淋巴细胞527.7 vs 248.3(p=0.04),均低于假注射组。
- DMM组BAL蛋白漏出1.48 vs 1.15 μg/μl(p=0.03),低于假注射组;EGX染色强度12,016 vs 15,186 arbitrary units(p=0.03),高于假注射组。
- 未治疗组体重下降3.7% vs 治疗组1.1%(p=0.04);DMM抑制MCP-1上调(1.66 vs 0.92 RE,p=0.02)和ICAM-1上调(1.40 vs 1.01 RE,p=0.05)。
- 作者认为DMM可能成为ARDS的新型治疗,其作用可能通过保护EGX及抑制MCP-1和ICAM-1介导。
适用人群与场景
- C57BL/6小鼠,经气管内给予67.7 μg脂多糖诱导ARDS模型。
处置流程与药物剂量
- 损伤后30分钟经尾静脉注射二甲基丙二酸(DMM)50 mg/kg,随后每日1次共3天;第4天行支气管肺泡灌洗(BAL)后处死动物。
研究设计与关键结果
- 研究类型为小鼠ARDS模型实验;DMM组n=8,假注射组n=8。
- BAL总细胞数:DMM组6.93×10^6 vs 假注射组2.46×10^6(p=0.04),DMM组少于假注射组。
- BAL巨噬细胞:DMM组168.6 vs 假注射组85.1(p=0.04),DMM组少于假注射组。
- BAL淋巴细胞:DMM组527.7 vs 假注射组248.3(p=0.04),DMM组少于假注射组。
- BAL蛋白漏出:DMM组1.48 vs 假注射组1.15 μg/μl(p=0.03),DMM组少于假注射组。
- EGX染色强度:DMM组12,016 vs 假注射组15,186 arbitrary units(p=0.03),DMM组高于假注射组。
- 体重下降:未治疗组3.7% vs 治疗组1.1%(p=0.04),未治疗组体重下降程度大于治疗组。
- MCP-1表达:DMM组0.92 RE vs 假注射组1.66 RE(p=0.02),DMM组低于假注射组;ICAM-1表达:DMM组1.01 RE vs 假注射组1.40 RE(p=0.05),DMM组低于假注射组。
证据类型、等级与局限
- 证据类型:小鼠ARDS模型实验研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为二甲基丙二酸可减轻ARDS肺部炎症和毛细血管渗漏,可能通过保护内皮糖萼及抑制单核细胞趋化蛋白-1和ICAM-1介导,可能成为ARDS的新型治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Succinate is a proinflammatory citric acid cycle metabolite that accumulates in tissues during pathophysiological states. Oxidation of succinate after ischemia-reperfusion leads to reversal of the electron transport chain and generation of reactive oxygen species. Dimethyl malonate (DMM) is a competitive inhibitor of succinate dehydrogenase, which has been shown to reduce succinate accumulation. We hypothesized that DMM would protect against inflammation in a murine model of ARDS.
METHODS: C57BL/6 mice were given ARDS via 67.7 μg of intratracheally administered lipopolysaccharide. Dimethyl malonate (50 mg/kg) was administered via tail vein injection 30 minutes after injury, then daily for 3 days. The animals were sacrificed on day 4 after bronchoalveolar lavage (BAL). Bronchoalveolar lavage cell counts were performed to examine cellular influx. Supernatant protein was quantified via Bradford protein assay. Animals receiving DMM (n = 8) were compared with those receiving sham injection (n = 8). Cells were fixed and stained with FITC-labeled wheat germ agglutinin to quantify the endothelial glycocalyx (EGX).
RESULTS: Total cell counts in BAL was less for animals receiving DMM (6.93 × 10 6 vs. 2.46 × 10 6 , p = 0.04). The DMM group had less BAL macrophages (168.6 vs. 85.1, p = 0.04) and lymphocytes (527.7 vs. 248.3; p = 0.04). Dimethyl malonate-treated animals had less protein leak in BAL than sham treated (1.48 vs. 1.15 μg/μl, p = 0.03). Treatment with DMM resulted in greater staining intensity of the EGX in the lung when compared with sham (12,016 vs. 15,186 arbitrary units, p = 0.03). Untreated animals had a greater degree of weight loss than treated animals (3.7% vs. 1.1%, p = 0.04). Dimethyl malonate prevented the upregulation of monocyte chemoattractant protein-1 (1.66 vs. 0.92 RE, p = 0.02) and ICAM-1 (1.40 vs. 1.01 RE, p = 0.05).
CONCLUSION: Dimethyl malonate reduces lung inflammation and capillary leak in ARDS. This may be mediated by protection of the EGX and inhibition of monocyte chemoattractant protein-1 and ICAM-1. Dimethyl malonate may be a novel therapeutic for ARDS.
参考来源
- Taghavi S, Campbell A, Engelhardt D, et al. Dimethyl malonate protects the lung in a murine model of acute respiratory distress syndrome. J Trauma Acute Care Surg. 2023. PMID: 37934622. doi:10.1097/TA.0000000000004184
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。